We evaluated HDAC1 (Supplementary Figure S1) and HDAC2 (Figure 2A) expression in both treatment-resistant and -responsive AML patient groups and revealed that HDAC2 expression was significantly increased in refractory group. This evidence concerns the gene HDAC2 and acute myeloid leukemia.